MRKR · Marker Therapeutics, Inc.

Cash flow dynamics further highlight operational efficiency, with net cash provided by operating activities using only -$1.4 million versus -$5.5 million in the prior-year period. This reduction in cash burn extends the company's liquidity runway into the first quarter of 2027, assuming no additional grant funds from new or existing awards. Management notes this estimate is subject to effective cost management, successful capital raises, and grant receipts, with no assurance provided. The company entered a Master Services Agreement with Cell Ready in February 2024 for product supply and services, supporting manufacturing needs for its pipeline.

Looking forward, Marker anticipates continued net losses as it invests in research and development, including clinical trials and marketing approval efforts for its product candidates, particularly MT-601 for lymphoma and MT-401 for AML. Expenses are expected to increase with these activities, and the operating plan may shift, potentially requiring funds sooner for product development and commercialization. To meet these needs, the company plans to fund operations through equity and/or debt financing. Liquidity remains contingent on cost controls and external capital, with operational risks tied to clinical progression and grant dependencies. This positions Marker to advance its non-genetically engineered multi-antigen T-cell therapies targeting heterogeneous tumors, balancing current improvements with future investment demands.